3BEJ,1OSV,1OT7


Conserved Protein Domain Family
NR_LBD_Fxr

?
cd06936: NR_LBD_Fxr 
Click on image for an interactive view with Cn3D
The ligand binding domain of Farnesoid X receptor:a member of the nuclear receptor superfamily of ligand-activated transcription factors.
The ligand binding domain (LBD) of Farnesoid X receptor: Farnesoid X receptor (FXR) is a member of the nuclear receptor superfamily of ligand-activated transcription factors. FXR is highly expressed in the liver, the intestine, the kidney, and the adrenals. FXR plays key roles in the regulation of bile acid, cholesterol, triglyceride, and glucose metabolism. Evidences show that it also regulates liver regeneration. Upon binding of ligands, such as bile acid, an endogenous ligand, FXRs bind to FXR response elements (FXREs) either as a monomer or as a heterodimer with retinoid X receptor (RXR), and regulate the expression of various genes involved in bile acid, lipid, and glucose metabolism. There are two FXR genes (FXRalpha and FXRbeta) in mammals. A single FXRalpha gene encodes four isoforms resulting from differential use of promoters and alternative splicing. FXRbeta is a functional receptor in mice, rats, rabbits and dogs, but is a pseudogene in humans and primates. Like other members of the nuclear receptor (NR) superfamily, farnesoid X receptors have a central well conserved DNA binding domain (DBD), a variable N-terminal domain, a non-conserved hinge and a C-terminal ligand binding domain (LBD).
Statistics
?
PSSM-Id: 132734
View PSSM: cd06936
Aligned: 7 rows
Threshold Bit Score: 369.543
Threshold Setting Gi: 82213639
Created: 19-Nov-2008
Updated: 17-Jan-2013
Structure
?
Program:
Drawing:
Aligned Rows:
 
Conserved site includes 14 residues -Click on image for an interactive view with Cn3D
Feature 1:ligand binding site [chemical binding site]
Evidence:

Sequence Alignment
?
Format: Row Display: Color Bits: Type Selection:
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
Feature 1                         #                  #  ## ##  #                                
3BEJ_A       13 PDQQTLLHFIMDSYNKQRMpqeitnkilkeefsaEENFLILTEMATNHVQVLVEFTKKLPGFqtLDHEDQIALLKGSAVE 92
gi 82213500 248 PEQQNLLDYIMDSYSKQQIpqevskkllheefsaEGNFLILTEMATSHVQVLVEFTKKLPGFqtLDHEDQIALLKGSAVE 327
gi 82213639 255 GEEYKLIDHIVTAHQKCGIslddmkmfleesadpEEIFYHFSEAAVLHVRAFVEFTKSLPGFemLDPLDQIALLKASTVE 334
gi 81895657 247 QEEHRLLNTIVTAHQKSMIplgetskllqegsnpELSFLRLSEVSVLHIQGLMKFTKGLPGFenLTTEDQAALQKASKTE 326
gi 82261468 238 TEQQALMRVITDAYNKHQIpqdvtkkllqdqystEENFLLLTEMATSQVQVLVEFTKNIPGFlsLDREDQIALLKGSAVE 317
1OSV_A        5 VDQQTLLDYIMDSYSKQRMpqeitnkilkeefsaEENFLILTEMATSHVQILVEFTKRLPGFqtLDHEDQIALLKGSAVE 84
1OT7_A        5 VDQQTLLDYIMDSYSKQRMpqeitnkilkeefsaEENFLILTEMATSHVQILVEFTKRLPGFqtLDHEDQIALLKGSAVE 84
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
Feature 1        ## ##  #                                                                       
3BEJ_A       93 AMFLRSAEIFNk------------------------------KLPSGh--SDLLEERIRNsgi----------------- 123
gi 82213500 328 AMFLRSAEIFSr------------------------------KLPTGh--TVLLEERIRNsgi----------------- 358
gi 82213639 335 AMLLRSAQIYNqsvmgstlqtteglarypshsvdfsqiqefdKCPLYsleAHPQEEDSTSstdl---------------- 398
gi 81895657 327 VMFLHVAQLYGt------------------------------MRPAKp-sAGTLEVHNPSadesvhspenflkegypsap 375
gi 82261468 318 AMFLRSAQALNk------------------------------KMPIGh--TEVLEERIHKsgi----------------- 348
1OSV_A       85 AMFLRSAEIFNk------------------------------KLPAGh--ADLLEERIRKsgi----------------- 115
1OT7_A       85 AMFLRSAEIFNk------------------------------KLPAGh--ADLLEERIRKsgi----------------- 115
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
Feature 1                                                                                       
3BEJ_A      124 ----sdeYITPMFSFYKSIgeLKMTQEEYALLTAIVILSPDRqyIKDREAVEKLQEPLLDVLQKLCkihqPENPQHFACL 199
gi 82213500 359 ----sdeFITPMFNFYKSIgeLKMTQEEYALLTAIVILSPDRqyIKDRESVERLQEPLLDILQKFCklhhPDNPQHFACL 434
gi 82213639 399 ----teeFITPLFNFFRSMgsLNVTEAEYALLSAVTVYFSDRplLQSKPHVEKLQEPLLGILHKYSrlyhPEDPQHFARL 474
gi 81895657 376 ltditkeFIASLSYFYRRMseLHVSDTEYALLTATTVLFSDRpcLKNKQHIENLQEPVLQLLFKFSkmyhPEDPQHFAHL 455
gi 82261468 349 ----seeFIKPMFNFYKSIgeLHMVLEEQALLTTITILTPDRpyVKDQPAVERLQENVLDLLRKMCvlhhPQEPQYFARL 424
1OSV_A      116 ----sdeYITPMFSFYKSVgeLKMTQEEYALLTAIVILSPDRqyIKDREAVEKLQEPLLDVLQKLCkiyqPENPQHFACL 191
1OT7_A      116 ----sdeYITPMFSFYKSVgeLKMTQEEYALLTAIVILSPDRqyIKDREAVEKLQEPLLDVLQKLCkiyqPENPQHFACL 191
                       250       260       270
                ....*....|....*....|....*....|....
Feature 1                    #             #      
3BEJ_A      200 LGRLTELRTFNHHHAEMLMSWRvndhkFTPLLCE 233
gi 82213500 435 LGRLTELRTFNHHHAEMLMSWRvndhkFTPLLCE 468
gi 82213639 475 IGRLTELRTLHHNHSEVLVLWKardtkLTPFAVW 508
gi 81895657 456 IGRLTELRTLSHSHSEILRMWKtkdprLVMLFSE 489
gi 82261468 425 LGRLTELRTLSHYHAEMLASWKvnnhkFTPLLCE 458
1OSV_A      192 LGRLTELRTFNHHHAEMLMSWRvndhkFTPLLCE 225
1OT7_A      192 LGRLTELRTFNHHHAEMLMSWRvndhkFTPLLCE 225

| Disclaimer | Privacy statement | Accessibility |
NCBI Home NCBI Search NCBI SiteMap